Literature DB >> 1493356

Aromatase inhibitors in malignant diseases of aging.

D C Johannessen1, P E Lønning.   

Abstract

Aromatase inhibition is an established endocrine treatment modality in postmenopausal breast cancer and is currently considered as an interesting experimental treatment approach in other malignant conditions such as endometrial carcinomas and prostatic cancer. While the 'classic' aromatase inhibitor aminoglutethimide causes many adverse effects that makes it unfit for use in elderly patients, several novel aromatase inhibitors with minimal adverse effects are currently being investigated. These drugs may provide important new tools in the endocrine treatment of malignant diseases in aging patients.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1493356     DOI： 10.2165/00002512-199202060-00008

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


  143 in total

1.  Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.

Authors:  M Dowsett; D C Cunningham; R C Stein; S Evans; L Dehennin; A Hedley; R C Coombes
Journal:  Cancer Res       Date:  1989-03-01       Impact factor: 12.701

2.  Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma.

Authors:  R J Santen; S Santner; B Davis; J Veldhuis; E Samojlik; E Ruby
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

Review 3.  Metabolism of estrogens--natural and synthetic.

Authors:  H M Bolt
Journal:  Pharmacol Ther       Date:  1979       Impact factor: 12.310

4.  Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age.

Authors:  D L Hemsell; J M Grodin; P F Brenner; P K Siiteri; P C MacDonald
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

5.  Aminoglutethimide and advanced breast cancer [proceedings].

Authors:  R C Mason; U Chetty; W R Miller; R A Hawkins; A P Forrest
Journal:  Biochem Soc Trans       Date:  1980-06       Impact factor: 5.407

6.  Estrone and estradiol content in human breast tumors: relationship to estradiol receptors.

Authors:  J Fishman; J S Nisselbaum; C J Menendez-Botet; M K Schwartz
Journal:  J Steroid Biochem       Date:  1977-08       Impact factor: 4.292

7.  Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.

Authors:  S Lundgren; P E Lønning; A Aakvaag; S Kvinnsland
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  The effect of the aromatase inhibitor, 4-(phenylthio)-4-androstene-3,17-dione, on dimethylbenz(A)anthracene-induced rat mammary tumors.

Authors:  Y J Abul-Hajj
Journal:  J Steroid Biochem       Date:  1989       Impact factor: 4.292

9.  Impact of continuously administered catechol estrogens on uterine growth and luteinizing hormone secretion.

Authors:  C P Martucci; J Fishman
Journal:  Endocrinology       Date:  1979-12       Impact factor: 4.736

10.  Treatment of metastatic breast cancer with aminoglutethimide.

Authors:  R F Asbury; R F Bakemeier; E Fölsch; C S McCune; E Savlov; J M Bennett
Journal:  Cancer       Date:  1981-04-15       Impact factor: 6.860
View more
  1 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.